Opposition says R&D Tax Credits bill seriously flawed
01 October, 2010 by David BinningShadow minister for innovation, industry, science and research Sophie Mirabella has hit back at government claims that the coalition is aiming a wrecking ball at its R&D Tax Credits legislation ‘sight unseen’.
Prima BioMed to list on NASDAQ
30 September, 2010 by David BinningCancer vaccines specialist Prima BioMed announced today that it is seeking a listing on NADSAQ, the world’s largest bourse for technology companies.
R&D Tax Credits bill reintroduced to parliament today
30 September, 2010 by David BinningScience and Innovation minister Senator Kim Carr has refused to rule out the possibility that the government’s battle weary R&D Tax Credits legislation may need to be further amended before coming into effect, while the coalition has vowed to maintain its efforts to block its passage.
APAC enjoying surge in VC funding
28 September, 2010 by Staff WritersVenture capital activity is growing strongly throughout the Asia pacific biomedical and biotech sectors at the same time as the US and Europe suffer sharp declines, according to industry database MedTRACK.
HPP launch tempered by GFC realities
24 September, 2010 by David BinningProfessor Mark Baker, co-chair of HUPO (Human Proteome Organisation) 2010 committee, has admitted that the Human Proteome Project (HPP) would have been further down the track today if it weren’t for the global financial crisis.
EMA says ‘no’ to Avandia
24 September, 2010 by David BinningThe European medicines agency announced overnight that it has suspended marketing authorisations for the anti-diabetes medicine Avandia (Rosiglitazone) citing research data linking the drug to increased risk of heart attack and stroke
Mesoblast shareholders approve Angioblast acquisition
23 September, 2010 by David BinningShareholders in regenerative medicine company Mesobast have voted almost unanimously in favour of the company acquiring its US subsidiary Angioblast Systems, increasing its 32.6 percent stake to full ownership.
Wollongong Uni researchers awarded US patent
16 September, 2010 by Staff WritersResearchers from the University of Wollongong’s (UOW) Schools of Chemistry and Health Sciences have been awarded a US patent for their novel method of characterising lipid molecules.
Market report: ASX down slightly despite another rally on Wall Street overnight
10 September, 2010 by David BinningThe Australian Stock Market just managed to stayed ahead for the week this week, as weakness from major sectors pushed down on the market.
Dr Christine Bennett named new chair of Research Australia
03 September, 2010 by Staff WritersResearch Australia today announced the appointment of Dr Christine Bennett as its new chair.
Ramsay reports strong FY profit jump
27 August, 2010 by Staff WritersAustralia’s biggest healthcare provider Ramsay Healthcare this week reported a 21.9 percent jump in full-year net profit to $178.5 million.
Argy-bargy continues at Avexa
27 August, 2010 by David BinningTroubled HIV drug developer Avexa may be poised for yet another coup after major shareholder Caldaza this week called for an extraordinary general meeting to discuss the future of the company
Mesoblast FY results reveal more red ink
26 August, 2010 by David BinningRegenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010, an increase on the previous year’s loss of $12.3 million.
Mesoblast reports FY net loss of $14.8 million
26 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast today reported a net loss of $14.8 million for the full year ended 30 June 2010. The company, noted, however that it had finished the year with cash reserves of $32.5 million, up from $16.5 million for the previous corresponding period.
Mesoblast to buy US partner Angioblast
24 August, 2010 by Staff WritersRegenerative medicine specialists Mesoblast announced this week that it has convened an extraordinary general meeting with shareholders to vote on the proposed acquisition of the company’s US partner Angioblast Systems.
